סך נכסי הפעילות העסקית Precision BioSciences, Inc. (DTIL)

Precision BioSciences (DTIL) is advancing genome editing innovations, leveraging collaborations with pharmaceutical industry leaders and the success of the ARCUS system in combating hepatitis B. Its U.S.-based research center is developing cutting-edge treatments for severe pathologies using unique molecular technologies. This chart illustrating value trends shows a total asset value of 117.43, while the company lacks pricing power due to a lack of sales and a dependence on grants.

Total assets represent the aggregate of the company's resources, calculated reverse-engineered via ROA to eliminate market noise and establish the actual balance of capital and liabilities. Analyzing the total assets chart allows an investor to detect business degradation in a timely manner, which in the case of Precision BioSciences (DTIL) confirms the effectiveness of the rigorous R&D expenditure audit conducted by management consisting of the industry's leading scientists.